News
BerGenBio announces interim biomarker and phase II clinical data with selective AXL inhibitor bemcentinib presented at ESMO
October 22, 2018
Biomarker predicts clinical benefit rate of 70% and overall response rate of 40% in second…
Read More
BerGenBio to present interim phase II clinical, preclinical and biomarker data with selective AXL inhibitor bemcentinib at ESMO
October 9, 2018
Bergen, Norway, 9 October 2018 - BerGenBio ASA (OSE:BGBIO) announces that the company and its…
Read More
BerGenBio enters second stage of phase II trial with selective AXL inhibitor bemcentinib in combination with KEYTRUDA® in patients with advanced NSCLC
October 5, 2018
Bergen, Norway, 5 October 2018 - BerGenBio ASA (OSE: BGBIO) announces that the first patient…
Read More
BerGenBio: Updated phII clinical data with selective AXL inhibitor bemcentinib strengthens its potential to improve NSCLC patient outcomes
September 25, 2018
Overall response rate of 40% with the bemcentinib/KEYTRUDA combination observed in AXL-positive, previously treated NSCLC…
Read More
BerGenBio to present interim phase 2 clinical data with selective AXL inhibitor bemcentinib in non-small cell lung cancer at WCLC
September 5, 2018
Bergen, Norway, 5 September 2018 - BerGenBio ASA (OSE:BGBIO) announces that the company and its…
Read More
BerGenBio ASA: Results for the Second Quarter and First Half 2018
August 21, 2018
Encouraging clinical data emerging from several phase II trials with highly selective AXL inhibitor bemcentinib…
Read More
Jonas Lies vei 91, 5009 Bergen, Norway
+ 47 559 61 159 (general) + 47 535 01 564 (urgent medical enquiries)